Outlook for obesity in 2025: more than a transition year US$ 24.68 Min. order: 1 piece ★★★★★ 4.0 (143 reviews) Sold : Login>>
Novo outlines new late-stage study of obesity drug CagriSema US$ 21.30 Min. order: 1 piece ★★★★★ 4.1 (175 reviews) Sold : Login>>
CagriSema Dual-Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP-1 receptor agonist), designed to influence key metabolic and appetite-regulating pathways. Current US$ 21.78 Min. order: 1 piece ★★★★★ 4.7 (140 reviews) Sold : Login>>
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints US$ 26.86 Min. order: 1 piece ★★★★★ 4.3 (72 reviews) Sold : Login>>
PDF] Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial US$ 26.23 Min. order: 1 piece ★★★★★ 4.2 (17 reviews) Sold : Login>>